Piperacillin-Tazobactam
- Generic Name
- Piperacillin-Tazobactam
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用于产β内酰胺酶而对哌拉西林耐药、但对本品敏感的细菌（如大肠埃希菌、克雷伯菌属、柠檬酸杆菌属、肠杆菌属、沙雷菌属、变形杆菌属、摩根菌属、雷极普罗维登菌、铜绿假单胞菌、流感嗜血杆菌、不动杆菌属、葡萄球菌属和拟杆菌属等）所致的下列中、重度感染：
1.肺炎、肺脓肿、脓胸、支气管扩张合并感染和慢性阻塞性肺病继发性感染等下呼吸道感染；
2.创伤或外科伤口继发皮肤软组织感染、蜂窝织炎、皮肤脓肿、糖尿病足感染；
3.胆囊炎、胆管炎、肝脓肿和腹膜炎等腹腔感染；
4.盆腔炎、子宫内膜炎、子宫周围炎、附件炎、盆腔脓肿等生殖系统感染；
5.单纯或复杂性尿路感染。本品用于铜绿假单胞菌严重感染时，应联合氨基糖苷类等其他抗铜绿假单胞菌的药物。
- Associated Conditions
- -
- Associated Therapies
- -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04983901
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 9
- Registration Number
- NCT04276480
- Locations
- 🇫🇷
Centre hospitalier de la Côte Basque, Bayonne, France
🇫🇷Hopital Pellegrin, Bordeaux, France
Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT03922451
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03862079
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03485950
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 962
- Registration Number
- NCT03269994
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Hackensack Meridian Health / Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 347
- Registration Number
- NCT03078010
- Locations
- 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 129
- Registration Number
- NCT02820987
- Locations
- 🇫🇷
Chu Besancon, Besançon, France
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 465
- Registration Number
- NCT02753946
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.